Search

Displaying results 6571 - 6580 of 8171 in total
  1. Drug

    JLK-247

    go.drugbank.com/drugs/DB17637
    Experimental

    JLK-247 is an adeno-associated viral vector serotype 9 (AAV9)-mediated gene replacement therapy for the treatment of Sanfilippo Syndrome Type C or MPS IIIC.[L46686]

  2. Drug

    JNJ-42165279

    go.drugbank.com/drugs/DB15173
    Investigational

    Jnj-42165279 is under investigation in clinical trial NCT02498392 (An Efficacy, Safety and Tolerability Study of JNJ-42165279 in Participants With Major Depressive Disorder With Anxious Distress).

  3. Drug

    Rabeximod

    go.drugbank.com/drugs/DB05772
    Investigational

    Rabeximod is an orally administered compound for treatment of moderate or severe active rheumatoid arthritis that is currently undergoing phase II clinical testing in eight European countries.

  4. Drug

    ENTR-601-44

    go.drugbank.com/drugs/DB17836
    Investigational

    ENTR-601-44 is an exon 44 skipping phosphorodiamidate morpholino oligonucleotide (PMO). Developed by Entrada Therapeutics, it was investigated for the treatment of Duchenne muscular dystrophy.[L46641]

  5. Drug

    GB-13

    go.drugbank.com/drugs/DB18387
    Experimental

    GB-13 is a genetically engineered recombinant protein consisting of an IL13Ra2-targeted genetically engineered mutant of IL-13 and PE4E, a derivative of Pseudomonas exotoxin A.

  6. Drug

    PAS-004

    go.drugbank.com/drugs/DB18611
    Investigational

    PAS-004 is an allosteric MEK 1/2 inhibitor being developed by Pasithea Therapeutics. It is being investigated for the treatment of neurofibromatosis 1 and Noonan syndrome.

  7. Drug

    Zonampanel anhydrous

    go.drugbank.com/drugs/DB20448
    Investigational

    Zonampanel anhydrous has a monoisotopic molecular weight of 331.06 Da.

  8. Drug

    Risovalisib

    go.drugbank.com/drugs/DB21474
    Investigational

    Risovalisib has a monoisotopic molecular weight of 598.19 Da.

  9. Drug

    Retezorogant

    go.drugbank.com/drugs/DB21592
    Experimental

    Retezorogant has a monoisotopic molecular weight of 420.22 Da.

  10. Drug

    Clascoterone

    go.drugbank.com/drugs/DB12499
    ApprovedInvestigational

    Clascoterone (cortexolone 17α-propionate, CB-03-01) is a novel antagonist of androgen receptors. It binds to androgen receptors with high affinity. By competing with androgens for binding to androgen receptors, clascoterone works by bloc...

    Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP2B6 Inhibitors